Phase II study of alemtuzumab–rituximab therapy in previously untreated patients with chronic lymphocytic leukemia: short- and long-term outcomes-Reference-Cited by-同舟云学术

Phase II study of alemtuzumab–rituximab therapy in previously untreated patients with chronic lymphocytic leukemia: short- and long-term outcomes

Published:2014-06-17 Issue:2 Volume:56 Page:315-323
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Frankfurt Olga,Ma Shuo,Gordon Leo,Winter Jane N.,Horowitz Jeanne M.,Rademaker Alfred,Weitner Bing Bing,Peterson LoAnn C.,Altman Jessica K.,Tallman Martin S.,Petrich Adam,Rosen Steven T.

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

http://www.tandfonline.com/doi/pdf/10.3109/10428194.2014.910654

Reference43 articles.

1. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

2. Early Results of a Chemoimmunotherapy Regimen of Fludarabine, Cyclophosphamide, and Rituximab As Initial Therapy for Chronic Lymphocytic Leukemia

3. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia

4. Rituximab therapy of patients with B-cell chronic lymphocytic leukemia

5. Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Measurable Residual Disease in Chronic Lymphocytic Leukemia: Current Understanding and Evolving Role in Clinical Practice;Current Treatment Options in Oncology;2023-05-17

2. Dual targeting fixed duration frontline monoclonal antibody therapy for chronic lymphocytic leukemia: A phase 2 study;Leukemia Research;2022-11

3. Flow cytometric evaluation of measurable residual disease in chronic lymphocytic leukemia: Where do we stand?;Hematological Oncology;2022-06-21

4. Measurable residual disease in chronic lymphocytic leukemia: expert review and consensus recommendations;Leukemia;2021-06-24

5. Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 4.2020;J NATL COMPR CANC NE;2020